Medtronic Achieves Regulatory Milestones for Revolutionary Cardiac Mapping Software
Medtronic, a global leader in healthcare technology, has recently announced significant regulatory achievements concerning its latest cardiac mapping solutions, particularly the Affera™ Prism-2 Mapping Software and the PulseSelect ProxBox™ Adapter with Proximity Indicator software. These milestones include the receipt of U.S. Food and Drug Administration (FDA) clearance and CE Mark for the Affera software, as well as the CE Mark approval for the PulseSelect ProxBox. These advancements are expected to greatly enhance the integration and robustness of cardiac ablation techniques available through Medtronic's offerings.
Khaldoun Tarakji, MD, MPH, who serves as Vice President and Chief Medical Officer at Medtronic’s Cardiac Ablation Solutions, emphasized the necessity for continuous innovation in mapping technologies, stating, "Innovation in mapping software is essential to realizing the full potential of cardiac ablation technologies and supporting the precision physicians seek during procedures." This integration aims to provide physicians with a more connected healthcare experience ultimately enhancing patient care for those dealing with heart rhythm disorders.
With the Affera Prism-2 Mapping Software, healthcare professionals can generate intricate three-dimensional maps highlighting the heart's electrical activity during procedures that treat arrhythmias or irregular heartbeats. The software utilizes advanced tracking techniques, including magnetic and impedance-based methods, which allow for the visualization of various diagnostic tools on a comprehensive three-dimensional mapping platform. This is particularly beneficial as it enables procedures to be conducted with minimal reliance on fluoroscopy, representing a potential breakthrough in reducing radiation exposure during cardiac interventions.
Among the new features introduced with this software release are advanced mapping tools such as Beat Matching, which assists in comparing heartbeats to detect abnormal signals, and Pace Tagging, which marks specific locations during pacing procedures. These enhancements are designed to aid physicians in visualizing and interpreting the electrical activity within the heart, facilitating effective mapping and informed decision-making throughout the ablation process. The Affera Mapping and Ablation System is utilized alongside the Sphere-9™ Catheter, a comprehensive device that integrates high-definition mapping capabilities with both dual-energy pulsed field and radiofrequency ablation technologies.
Additionally, the PulseSelect ProxBox™ Adapter, equipped with a Proximity Indicator, offers real-time feedback based on impedance to help physicians determine whether their catheter is in close proximity to the targeted heart tissue prior to delivering energy during the ablation process. This innovative feature enhances procedural safety and effectiveness by ensuring precise targeting of cardiac tissue. Notably, the PulseSelect PFA System is recognized for being the first pulsed field ablation catheter to receive FDA approval and is currently utilized in over 60 countries worldwide.
Rebecca Seidel, the Senior Vice President and President of Electrophysiology Therapies at Medtronic, affirmed the significance of software excellence as a foundational aspect of their electrophysiology endeavors, stating, "Software excellence is a priority across our electrophysiology business and is central to the integrated experience physicians expect." Together, these recent regulatory achievements signify major strides in advancing Medtronic’s software capabilities, alongside an ongoing expansion of its cardiac ablation technology portfolio.
Medtronic's commitment to addressing challenging health issues resonates through their Mission, which is to alleviate pain, restore health, and prolong life. Backed by a dedicated workforce of over 95,000 individuals spread across 150 countries, the company continuously seeks innovative solutions to transform healthcare outcomes.
In conclusion, Medtronic’s latest developments in cardiac mapping and ablation software not only promise to augment the precision of cardiac procedures but also herald a new era in how heart rhythm disorders are approached and treated. As we continue to witness technological advancements, the potential for improved patient outcomes in cardiology is promising. For more information on Medtronic and their innovations, visit their official website at Medtronic.com.
Khaldoun Tarakji, MD, MPH, who serves as Vice President and Chief Medical Officer at Medtronic’s Cardiac Ablation Solutions, emphasized the necessity for continuous innovation in mapping technologies, stating, "Innovation in mapping software is essential to realizing the full potential of cardiac ablation technologies and supporting the precision physicians seek during procedures." This integration aims to provide physicians with a more connected healthcare experience ultimately enhancing patient care for those dealing with heart rhythm disorders.
With the Affera Prism-2 Mapping Software, healthcare professionals can generate intricate three-dimensional maps highlighting the heart's electrical activity during procedures that treat arrhythmias or irregular heartbeats. The software utilizes advanced tracking techniques, including magnetic and impedance-based methods, which allow for the visualization of various diagnostic tools on a comprehensive three-dimensional mapping platform. This is particularly beneficial as it enables procedures to be conducted with minimal reliance on fluoroscopy, representing a potential breakthrough in reducing radiation exposure during cardiac interventions.
Among the new features introduced with this software release are advanced mapping tools such as Beat Matching, which assists in comparing heartbeats to detect abnormal signals, and Pace Tagging, which marks specific locations during pacing procedures. These enhancements are designed to aid physicians in visualizing and interpreting the electrical activity within the heart, facilitating effective mapping and informed decision-making throughout the ablation process. The Affera Mapping and Ablation System is utilized alongside the Sphere-9™ Catheter, a comprehensive device that integrates high-definition mapping capabilities with both dual-energy pulsed field and radiofrequency ablation technologies.
Additionally, the PulseSelect ProxBox™ Adapter, equipped with a Proximity Indicator, offers real-time feedback based on impedance to help physicians determine whether their catheter is in close proximity to the targeted heart tissue prior to delivering energy during the ablation process. This innovative feature enhances procedural safety and effectiveness by ensuring precise targeting of cardiac tissue. Notably, the PulseSelect PFA System is recognized for being the first pulsed field ablation catheter to receive FDA approval and is currently utilized in over 60 countries worldwide.
Rebecca Seidel, the Senior Vice President and President of Electrophysiology Therapies at Medtronic, affirmed the significance of software excellence as a foundational aspect of their electrophysiology endeavors, stating, "Software excellence is a priority across our electrophysiology business and is central to the integrated experience physicians expect." Together, these recent regulatory achievements signify major strides in advancing Medtronic’s software capabilities, alongside an ongoing expansion of its cardiac ablation technology portfolio.
Medtronic's commitment to addressing challenging health issues resonates through their Mission, which is to alleviate pain, restore health, and prolong life. Backed by a dedicated workforce of over 95,000 individuals spread across 150 countries, the company continuously seeks innovative solutions to transform healthcare outcomes.
In conclusion, Medtronic’s latest developments in cardiac mapping and ablation software not only promise to augment the precision of cardiac procedures but also herald a new era in how heart rhythm disorders are approached and treated. As we continue to witness technological advancements, the potential for improved patient outcomes in cardiology is promising. For more information on Medtronic and their innovations, visit their official website at Medtronic.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.